Opinion|Videos|November 16, 2026

Setting HS Treatment Goals and Building a Multimodal Regimen

Setting realistic expectations helps patients recognize improvement and stay on therapy. For moderate to severe HS, a biologic anchors a multimodal plan that addresses each contributing disease pathway.

In "Setting HS Treatment Goals and Building a Multimodal Regimen," Jennifer Hsiao, MD opens the interview by explaining how she frames treatment for newly diagnosed patients.

Dr. Hsiao, a dermatologist at the University of Southern California who co-directs an HS specialty clinic, begins by stressing the importance of setting appropriate treatment expectations when a patient with HS starts a medication. She explains that current therapies are not expected to make tunnels or areas of permanent tissue destruction melt away. Instead, medications focus on treating the active inflammation that drives disease activity and symptoms.

She tells patients what she hopes to hear at the next visit: decreased pain, decreased drainage, and fewer new lesions. Any new lesions should be smaller and should go away more quickly. She frames success as reduced flare severity, duration, and frequency, and she finds that this language helps patients know what improvement looks like. It also supports adherence, because patients understand what the treatment can and cannot do. Procedural therapies can be combined with medical therapy to achieve even higher levels of outcome.

For moderate to severe HS, Dr. Hsiao thinks in terms of treatment buckets, each targeting a different contributing factor. These include immune dysregulation, which is the core pathway that must be brought under control, as well as follicular occlusion, metabolic and hormonal dysfunction, dysbiosis, and environmental triggers. She says one of the FDA-approved biologics should be the core therapy of the regimen.

Clinicians can then layer in adjunct therapies to optimize outcomes. She suggests a metabolic agent such as metformin or a GLP-1 agonist, and she suggests spironolactone or another hormonal modulator. Procedural therapies form the final bucket, used to tackle persistent lesions that do not respond to medical therapy. Dr. Hsiao concludes that HS requires a multimodal approach, with a biologic as the core around which the treatment plan is built.

Our next episode, "Choosing an HS Biologic: Comorbidities, Access, and Adherence Barriers," turns to how Dr. Hsiao chooses among the approved biologics and what gets in the way of starting them.


Related to this article